BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 16940271)

  • 1. Use of memantine to treat Alzheimer's disease.
    Gauthier S; Herrmann N; Ferreri F; Agbokou C
    CMAJ; 2006 Aug; 175(5):501-2. PubMed ID: 16940271
    [No Abstract]   [Full Text] [Related]  

  • 2. Memantine for Alzheimer's disease.
    Med Lett Drugs Ther; 2003 Sep; 45(1165):73-4. PubMed ID: 12968123
    [No Abstract]   [Full Text] [Related]  

  • 3. Tolerability of switching from donepezil to memantine treatment in patients with moderate to severe Alzheimer's disease.
    Waldemar G; Hyvärinen M; Josiassen MK; Kørner A; Lehto H; Wetterberg P
    Int J Geriatr Psychiatry; 2008 Sep; 23(9):979-81. PubMed ID: 18229874
    [No Abstract]   [Full Text] [Related]  

  • 4. I remember.
    Ladouceur R
    Can Fam Physician; 2006 Feb; 52():155. PubMed ID: 16529383
    [No Abstract]   [Full Text] [Related]  

  • 5. Another perspective on the memantine graphs: clinical vs. statistical significance.
    Davis S
    Med Health R I; 2005 Jan; 88(1):12-4; discussion 14. PubMed ID: 15779549
    [No Abstract]   [Full Text] [Related]  

  • 6. [Alzheimer dementia. Memantine: value for patient and caregivers].
    MMW Fortschr Med; 2009 Nov; 151(45):44-5. PubMed ID: 19960725
    [No Abstract]   [Full Text] [Related]  

  • 7. The place of memantine in the treatment of Alzheimer's disease: a number needed to treat analysis.
    Livingston G; Katona C
    Int J Geriatr Psychiatry; 2004 Oct; 19(10):919-25. PubMed ID: 15449303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Anti-dementia therapy pays at every stage of the disease. Patients with Alzheimer's disease stay all-day fit longer].
    MMW Fortschr Med; 2003 May; 145 Suppl 2():113. PubMed ID: 14579507
    [No Abstract]   [Full Text] [Related]  

  • 9. [Memantine in the pharmacologic treatment of moderately severe to severe Alzheimer's disease in Spain (MEMORY study)].
    Agüera-Ortiz LF;
    Rev Neurol; 2010 Nov; 51(9):525-34. PubMed ID: 20979032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [New options for the pharmacotherapy of Alzheimer's disease after the registration of memantine?].
    Frölich L; Schmitt B; Calabrese P; Diener H; Förstl H; Gertz HJ; Hallauer JF; Hampel H; Ihl R; Rieke K; Riepe M; Supprian T
    Dtsch Med Wochenschr; 2005 Feb; 130(8):408-12. PubMed ID: 15717252
    [No Abstract]   [Full Text] [Related]  

  • 11. Incidence of cholinergic and memantine treatment in Alzheimer's disease in Finland.
    Virta L; Viramo P
    J Am Geriatr Soc; 2007 Nov; 55(11):1886-7. PubMed ID: 17979907
    [No Abstract]   [Full Text] [Related]  

  • 12. Memantine in moderate to severe Alzheimer's disease: a meta-analysis of randomised clinical trials.
    Winblad B; Jones RW; Wirth Y; Stöffler A; Möbius HJ
    Dement Geriatr Cogn Disord; 2007; 24(1):20-7. PubMed ID: 17496417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer's disease.
    Wilkinson D; Andersen HF
    Dement Geriatr Cogn Disord; 2007; 24(2):138-45. PubMed ID: 17622761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different conclusions about memantine.
    Lexchin J
    Can Fam Physician; 2007 Mar; 53(3):403-4; author reply 404. PubMed ID: 17872671
    [No Abstract]   [Full Text] [Related]  

  • 15. Donepezil in severe Alzheimer's disease.
    Winblad B
    Am J Alzheimers Dis Other Demen; 2009; 24(3):185-92. PubMed ID: 19246572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Memantine: a review of its use in Alzheimer's disease.
    Robinson DM; Keating GM
    Drugs; 2006; 66(11):1515-34. PubMed ID: 16906789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clock drawing and frontal lobe behavioral effects of memantine in Alzheimer's disease: a rater-blinded study.
    Paskavitz JF; Gunstad JJ; Samuel JE
    Am J Alzheimers Dis Other Demen; 2006 Dec-2007 Jan; 21(6):454-9. PubMed ID: 17267379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment strategies for the behavioral symptoms of Alzheimer's disease: focus on early pharmacologic intervention.
    Beier MT
    Pharmacotherapy; 2007 Mar; 27(3):399-411. PubMed ID: 17316151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antipsychotic dose-sparing effect with addition of memantine.
    Sleeper RB
    Ann Pharmacother; 2005 Sep; 39(9):1573-6. PubMed ID: 16076907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of degenerative dementia disorders--who should be treated?].
    Hasselbalch SG; Kampmann JP
    Ugeskr Laeger; 2009 Mar; 171(10):802-5. PubMed ID: 19265606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.